NCT06313190View on ClinicalTrials.gov

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2030

Conditions
Hepatocellular Carcinoma
Interventions
RADIATION

Stereotactic body radiotherapy

Patients in both cohorts will receive SBRT using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3 fractions over 1 week.

DRUG

Sintilimab

Patients received sintilimab 200 mg every 3 weeks for up to 6 cycles, with the first dose within 1 week after the completion of SBRT.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

Ningbo Medical Center Lihuili Eastern Hospital

UNKNOWN

lead

Sun Yat-sen University

OTHER